Cancer

Photo

Article • Hengrui Pharma charts its global strategy at ESMO

Meet the Chinese company advancing European oncology

Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets. At the ESMO congress in Berlin, Yuting (Shelley) Liu, Head of China Business Development and Strategy of Hengrui Pharma, shared insights into how the company is translating decades of Chinese market experience into a global oncology strategy.

Photo

Article • Reshaping GI cancer care

Pathologists at the heart of precision oncology

Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, according to experts presenting at the 37th European Congress of Pathology in Vienna this September. During a session on state-of-the-art in gastrointestinal biomarkers, speakers outlined how targeted therapies and immunotherapies are transforming treatment options – but…

Photo

Article • From H&E to multiplex

Self-learning AI: a boost for digital pathology

Self-learning artificial intelligence approaches are offering a number of advantages for digital pathology when compared to established AI options. The benefits, which range from greater speed and capacitive flexibility to ‘wholly interpretable’ analyses, were outlined at the Digital Pathology and AI Congress in London.

979 show more articles
Subscribe to Newsletter